Abstract
According to WHO data about 2 billion people in the world suffer from anemia, that is 1/3 of the whole population of the planet. Causes of anemic states are varied and often they complement each other, iron deficiency anemia (IDA) which occurs in 75-80% of cases is of the greatest significance among anemias of different origins. Anaemia is a frequent systemic manifestation of inflammatory bowel diseases (IBD) which significantly worsens quality of life, it is associated with disease severity and resistance to therapy. The article highlights pathogenesis and diagnosis of anaemia in IBD patients based on current understanding of iron homeostasis in chronic inflammation. 69 anemic patients with IBD compared to with 30 patients with normal Hb level were under investigation. The control group consisted of 15 healthy individuals. The examination included total blood count, parameters of iron metabolism (serum iron, unsaturated and total iron binding capacity, trasferrin saturation, ferritin), as well as hepcidin-25 level and erythropoetin in serum. Depending on sTfR/log ferritin index the patients were divided into groups: 44% with IDA, 34 % – anemia of chronic disease (ACD) and 22 % – combination of IDA and ACD. A significant decrease of hepcidine-25 level in serum of IDA patients and increase of that one against inflammatory process in patients with ACD and ACD+IDA was found being. An increase of erythropoetin production was established in anemic patients, less expressed on ACD background.
Highlights
According to WHO data about 2 billion people in the world suffer from anemia, that is 1/3 of the whole population of the planet
Causes of anemic states are varied and often they complement each other, iron deficiency anemia (IDA) which occurs in 75-80% of cases is of the greatest significance among anemias of different origins
Anaemia is a frequent systemic manifestation of inflammatory bowel diseases (IBD) which significantly worsens quality of life, it is associated with disease severity and resistance to therapy
Summary
Ɉɪɢ ɞɟɮɿɰɢɬɿ ɡɚɥɿɡɚ ɡɛɿɥɶɲɭɽɬɶɫɹ ɟɤɫɩɪɟɫɿɹ TfR ɧɚ ɤɥɿɬɢɧɧɢɯ ɦɟɦɛɪɚɧɚɯ ɿ, ɜɿɞɩɨɜɿɞɧɨ, ɪɿɜɟɧɶ sTfR ɭ ɤɪɨɜɿ. Ɉɪɢ ɬɚɤ ɡɜɚɧɿɣ ɚɧɟɦɿʀ ɯɪɨɧɿɱɧɨɝɨ ɡɚɯɜɨɪɸɜɚɧɧɹ (ȺɏɁ), ɹɤɚ ɜɢɧɢɤɚɽ ɧɚ ɮɨɧɿ ɚɤɬɢɜɚɰɿʀ ɿɦɭɧɧɨʀ ɫɢɫɬɟɦɢ ɿ ɩɪɨɞɭɤɰɿʀ ɩɪɨɡɚɩɚɥɶɧɢɯ ɰɢɬɨɤɿɧɿɜ, ɜɿɞɛɭɜɚɽɬɶɫɹ ɧɚɤɨɩɢɱɟɧɧɹ ɡɚɥɿɡɚ ɜ ɦɚɤɪɨɮɚɝɚɯ, ɜɧɚɫɥɿɞɨɤ ɱɨɝɨ ɜɨɧɨ ɫɬɚɽ ɧɟɞɨɫɬɭɩɧɢɦ ɞɥɹ ɟɪɢɬɪɨɩɨɟɡɭ, ɮɨɪɦɭɽɬɶɫɹ «ɮɭɧɤɰɿɨɧɚɥɶɧɢɣ ɡɚɥɿɡɨɞɟɮɿɰɢɬ». Ɇɚ ɮɨɧɿ ɚɤɬɢɜɧɨʀ ɡɚɩɚɥɶɧɨʀ ɜɿɞɩɨɜɿɞɿ ɞɢɫɤɪɢɦɿɧɚɰɿɣɧɢɦ ɡɧɚɱɟɧɧɹɦ ɰɶɨɝɨ ɿɧɞɟɤɫɭ ɜɜɚɠɚɽɬɶɫɹ 2, ɨɫɤɿɥɶɤɢ ɜɦɿɫɬ ɮɟɪɢɬɢɧɭ, ɹɤ ɛɿɥɤɚ ɝɨɫɬɪɨʀ ɮɚɡɢ, ɩɿɞɜɢɳɭɽɬɶɫɹ ɩɪɢ ɡɚɩɚɥɟɧɧɿ, ɧɟɡɚɥɟɠɧɨ ɜɿɞ ɡɚɩɚɫɿɜ ɡɚɥɿɡɚ ɜ ɨɪɝɚɧɿɡɦɿ [17].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.